Systemic sclerosis (scleroderma) is a relatively rare but systemic autoimmune disease which is characterized by the tightening and thickening of the skin – a process which often afflicts internal organs as well such as the lung, gastrointestinal tract, or kidney. It affects only 300,000 people in the U.S., but may often lead to significant morbidity related to skin disease, including restrictions in mobility, or even death due to lung or kidney failure.
Currently, no cure exists for scleroderma, although many immunosuppressive medications have been successfully used. At BRI, research programs study the cells and immune processes thought to regulate scleroderma in an effort to further understanding of disease pathogenesis, translating these findings into therapeutic targets. In addition, clinical trials are ongoing to evaluate novel therapies in this disease.
For more information on scleroderma at Benaroya Research Institute, search on the disease below.
Look for clinical research trials for scleroderma.